Skip to main content
OpenTrials
Completed

NCT Number: NCT03574961

E-Support Groups in Multiple Sclerosis

Primary objectives:

* To determine the feasibility of program (80% retained with 75% overall attendance, and completed immediate follow-up questionnaires from 75% of participants). * To determine the efficacy of program (evaluated by decreased loneliness, operationalized as decreased total score on the UCLA Loneliness Scale from pre to post intervention).

Secondary objective:

* To determine whether program will affect depression and quality of life.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Columbia University Medical Center (MS Center)

New York, 10032, United States

About this study

This study involves prospective data collection from an intervention to investigate the impact of participation by MS patients in a 12-week guided online social support group. All outcomes will be compared to active control group. At the completion of a 12-week interval, all participants (placebo and treatment) will complete follow-up questionnaires. Three months after completing, participants will be sent follow-up questionnaires that will be evaluated as a 6-month follow-up, to assess retention of benefits.

Social support has been linked to better health outcomes in many clinical populations. Multiple sclerosis (MS), a chronic neurological disease that affects over 400,000 people in the United States, involves physical and cognitive disability that can have negative consequences on social integration. This can lead to social isolation, which may be dynamically related to depression, fatigue, and disease progression. The aim of the present study is to investigate the impact of support group involvement on persons with MS. Outcomes of interest include mood, loneliness, and quality of life (QOL). Many people with MS feel isolated and are unable to participate in support groups that meet in locations that may be far from home, difficult to travel to (due to physical disability or lack of resources), or may not be convenient for their schedules. Another hindrance is the apprehension that MS patients sometimes experience when they encounter patients with severe physical disability, or worse impairment than their own. For these reasons, the study is introducing remote support groups to be conducted via the internet, "e-Support." Attending a remote, internet based support group may be more appealing to patients with MS as it obviates the need to travel, thereby reducing cost, time, and energy.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of MS (any disease type)
  • Age 18 or over
  • Willingness to sign informed consent document

Exclusion criteria

  • Unable to obtain access to the internet

Treatment and study plan

e-Support group

Behavioral

Online (remote), web-based support group via private video link.

Other names: e-Support

e-Journaling placebo

Behavioral

Online journaling activity.

Other names: e-Journaling

Primary outcomes

  1. Percentage of enrolled participants who completed follow-up questionnaires

    Time frame: 12 weeks

    Assess feasibility of the program: to retain and obtain completed questionnaires at immediate follow-up from 80% of enrolled participants (meeting the criteria of 75% attendance).

  2. Change in UCLA Loneliness Scale total score (please note that the official name of the scale is the UCLA Loneliness Scale).

    Time frame: Baseline, 12 weeks (immediate follow-up)

    Assess efficacy of the program to decrease loneliness as defined by a significant decrease in total score on UCLA Loneliness Scale. This name never appears as anything other than UCLA Loneliness Scale, i.e. Russell 1996)

Secondary outcomes

  1. Change in overall depression [Patient Health Questionnaire (PHQ-9)] total score

    Time frame: Baseline, 12 weeks

    Assess efficacy of the program to decrease depression as defined by a significant decrease in total score on Patient Health Questionnaire (PHQ-9): an efficient tool for depression screening. The scale ranges from 0-27, with higher scores indicating worse depression.

  2. Change in overall Functional Assessment of Multiple Sclerosis Quality of Life (FAMS QoL) score

    Time frame: Baseline, 12 weeks

    Assess efficacy of the program to improve quality of life. The Functional Assessment of Multiple Sclerosis (FAMS) quality of life (QoL) instrument is a disease-specific, self-report questionnaire. It includes 7 subscales. The total score is generated by summing scores across all subscales, and ranges from 0-232, with higher scores reflective or worse overall function. In addition to considering a significant decrease in the total score as an indication of better overall function, we will separately examine each subscale to see whether decreases in score (indicating improvements in function) are shown. This includes the following subscales: mobility, symptoms, emotional well-being, general contentment, thinking and fatigue, family/social well-being, and additional concerns scales.

Sponsors and collaborators

Lead sponsor

Columbia University

Other

Collaborators

  • National Multiple Sclerosis Society

Registry information

Official study title

A Randomized Controlled Trial of e-Support in Persons With Multiple Sclerosis

Acronym: eSupport

Important dates

Study start
2018
Primary completion
2019
Study completion
2019
First posted
Jul 2, 2018
Registry last updated
Sep 1, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.